Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Gov't to Relax Belt-Tightening Fiscal Policy
December 15, 2008
- REGULATORY NEWS IN BRIEF
December 15, 2008
- VITAL KSK Holdings Aims at Sales of \600 Bil. in FY2012
December 8, 2008
- JACDS Objects to JODA's Voluntary GLs
December 8, 2008
- Price Negotiations Make Little Headway at Major Hospitals
December 8, 2008
- DPJ's Council Favors Restrictions of Online Sales of Drugs
December 8, 2008
- Yakult Honsha: Strong Sales of Elplat Prop Up Pharma Business
December 8, 2008
- Creams for Vaginal Candidiasis Recommended for Approval as Switch OTC Drugs
December 8, 2008
- TOP QUARK to Provide Int'l Clinical Development Project Management Services
December 8, 2008
- SELF-MEDICATION NEWS IN BRIEF
December 8, 2008
- Licensing Negotiations Underway for Drug for MS: MediciNova
December 8, 2008
- Annual Breast Cancer Examination Recommended for Patients on HRT
December 8, 2008
- BUSINESS NEWS IN BRIEF
December 8, 2008
- Children with SGA Short Stature Require Early Treatment: Pfizer Seminar
December 8, 2008
- MOF Proposes Carrot-and-Stick Approach to Encourage Insurers to Use More Generics
December 8, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 8, 2008
- Share of Generics Too Low: MOF Council
December 8, 2008
- 2 Drugs for CML, 2 Anti-HIV Drugs Recommended for Approval
December 8, 2008
- REGULATORY NEWS IN BRIEF
December 8, 2008
- NBI Opens Research Institute in Kobe
December 8, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…